Live
- Bad air: 106 shuttle buses, 60 extra Metro trips planned to make Delhiites give up cars
- WHO reports declining monkeypox cases in Congo
- CM Attends Kotideepotsavam on Kartika Purnima
- PKL Season 11: Raiding trio of Devank, Ayan, Sandeep help Patna Pirates rout Bengal Warriorz
- Food waste crisis fuels sustainable practices across APAC food & beverage industry: Report
- AI helps erase racist deed restrictions in California
- ATMIS completes third phase of troops' drawdown in Somalia
- PM Kisan Samman Nidhi scheme bringing smile to Nalanda farmers
- German economy forecast to lag eurozone growth until 2026
- CM Shinde orders stern action against hoarding of onions amid rising prices
Suven Life secures two new patents
City-based Suven Life Sciences has been granted a patent each by Europe and Macau for drug used in the treatment of disorders associated with neurodegenerative diseases.
Hyderabad: City-based Suven Life Sciences has been granted a patent each by Europe and Macau for drug used in the treatment of disorders associated with neurodegenerative diseases. "The company has been granted one product patent from Europe and one product patent from Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases", Suven Life said in a statement.
The patents are valid through 2030 and 2029. "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for major depressive disorder (MDD) with high unmet medical need with a huge market potential globally",said Venkat Jasti,CEO, Suven Life.
With these new patents, Suven has a total of 20 granted patents from Europe and 8 from Macau. These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II, the company said.
